| Delyna Rae Bohnenblust, ARNP | |
|
509 N 32nd Street, Attamont, KS 67330 | |
| (620) 784-5562 | |
| Not Available |
| Full Name | Delyna Rae Bohnenblust |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 509 N 32nd Street, Attamont, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649335928 | NPI | - | NPPES |
| 161305 | Other | KS | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 74052 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Delyna Rae Bohnenblust, ARNP 509 N 32nd Street, Attamont, KS 67330 Ph: (620) 784-5562 | Delyna Rae Bohnenblust, ARNP 509 N 32nd Street, Attamont, KS 67330 Ph: (620) 784-5562 |
News Archive
"The team has isolated a unique set of active molecules from Taipan venom and research shows they are extremely effective at easing the heart's workload," he said.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
Jeffery Dusek, PhD, Director of Research at University Hospitals (UH) Connor Integrative Health Network and Associate Professor in the Department of Family Medicine and Community Health at Case Western Reserve University, and colleagues were recently awarded a 3-year, $2+ million grant from the National Center of Complementary and Integrative Health, part of the National Institutes of Health.
"Malaria prevention advocates say many lives can be saved by removing taxes and tariffs from essential commodities used to fight the disease," VOA News reports. A decade ago, African leaders promised to remove tariffs on products used to fight malaria, but only six countries have actually done so, according to the Malaria Taxes and Tariffs Advocacy Project, which held a meeting in Geneva on Wednesday, Reuters reports.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.
› Verified 8 days ago